Current stock page

Financial Data

REPL Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

REPLReplimune Group, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$21.89−$0.09 (−0.41%)

Latest quote

  • Momentum
    97
  • Value
    —
  • Quality
    35
  • Risk resilience
    26
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0$0$0$0-$848K$0
Operating Income-$56.28M-$68.25M-$73.34M-$71.87M-$84.29M-$90.42M-$79.88M-$66.02M
Net Income-$57.12M-$69.77M-$73.22M-$70.93M-$83.1M-$86.69M-$74.13M-$66.34M
EPS-$0.54-$0.72-$0.76-$0.77-$0.9-$0.95-$0.96-$0.79
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$47.7M-$75.73M-$56.16M-$65.96M-$81.21M-$77.02M-$53.73M-$50.71M
Capital Expenditure-$77K-$6K-$5K-$135K-$1.34M-$2.74M-$1.13M-$1.8M
Free Cash Flow-$47.78M-$75.73M-$56.17M-$66.09M-$82.56M-$79.76M-$54.87M-$52.51M
Net Cash Provided By Operating Activities-$47.7M-$75.73M-$56.16M-$65.96M-$81.21M-$77.02M-$53.73M-$50.71M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$373.94M$252.45M$332.39M$333.59M$389.45M$469.51M$551.33M$603.63M
Total Debt$127.19M$111.98M$111.59M$76.35M$76.32M$76.33M$76.17M$76.04M
Cash And Cash Equivalents$307.83M$185.36M$209.02M$122.95M$102.3M$97.37M$111.12M$172.25M
Total Liabilities$169.16M$146.8M$166.23M$123.05M$126.11M$132.79M$135.49M$121.25M
Total Stockholders Equity$204.78M$105.65M$166.16M$210.54M$263.34M$336.72M$415.84M$482.37M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.2513.736.263.232.971.491.72.39
P/S ratio————————
Debt To Equity0.621.060.670.360.290.230.180.16
Free Cash Flow Yield-14.55%-19.35%-27.38%-41.64%-34.52%-45.43%-28.19%-16.67%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.2513.736.263.232.971.491.72.39
P/S ratio————————
Return On Equity-132.36%-281.14%-188.94%-149.55%-117.82%-83.22%-59.47%-47.32%
Debt To Equity0.621.060.670.360.290.230.180.16

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-7.85x
Pb11.24x
EPS Growth Yoy40.00%
Gross Margin0.00%
Operating Margin0.00%
ROE-157.78%
ROIC-80.89%
Debt To Equity0.62
FCF Yield-11.84%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$21.89
Volume2.02M
RSI (14)72.07
MACD2.5
MACD signal2.06
MACD histogram0.44
ADX (14)42.85
SMA (50)$14.76
SMA (200)$10.00
ATR (14)$1.33
Historical volatility (annualized)100.62%
Volume (20-day average)3.41M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score26/100
Beta0.9
Annual volatility187.93%
Max Drawdown-84.16%
Sharpe Ratio1.3
VaR (95%, 1-day)-8.22%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

REPL Financial Data FAQ

What is Replimune Group, Inc.'s revenue?

Replimune Group, Inc.'s revenue is one of the core financial data points for REPL. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Replimune Group, Inc.'s revenue growing?

Revenue growth shows whether Replimune Group, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is REPL's EPS?

REPL's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Replimune Group, Inc.'s net income?

Replimune Group, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Replimune Group, Inc. generate?

Free cash flow shows how much cash Replimune Group, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Replimune Group, Inc. have?

Cash and debt help frame REPL's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.